Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q2 2023 · 10-Q
Revenue$1.64M$1.64M−97.8% vs Q2 2022 Net Income-$160.70M-$160.70MN/M vs Q2 2022 EPS Diluted-$0.98-$0.98N/M vs Q2 2022 Operating Income-$146,099,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$113,781,000N/M Margins · derivedOperating margin-8903.0%−8794.3 pt vs Q2 2022
Net margin-9793.0%−9789.5 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end